SAGE 718

Drug Profile

SAGE 718

Alternative Names: SAGE-718

Latest Information Update: 10 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SAGE Therapeutics
  • Class Small molecules
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Smith-Lemli-Opitz syndrome
  • Preclinical Encephalitis

Most Recent Events

  • 27 Apr 2017 Phase-I clinical trials in Smith-Lemli-Opitz syndrome (In volunteers) in USA (PO)
  • 20 Nov 2016 Preclinical trials in Encephalitis in USA (PO)
  • 20 Nov 2016 Preclinical trials in Smith-Lemli-Opitz syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top